^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CHM 1101

    i
    Other names: CHM 1101, CLTX-CAR T cell therapy, Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes, CHM1101, CHM-1101
    Associations

    News

    Trials
    Company:
    Chimeric Therap, City of Hope
    Drug class:
    CLTX-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    23d
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial primary completion date: Sep 2024 --> Aug 2025
    Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    5ms
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Chimeric Therapeutics | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2024 --> Oct 2025
    Enrollment closed • Trial primary completion date • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    10ms
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2026 --> Sep 2025 | Trial primary completion date: Aug 2026 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    10ms
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    12ms
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Chimeric Therapeutics
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    1year
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Chimeric Therapeutics | Phase classification: P1b --> P1
    Phase classification • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    1year
    Initial clinical experience with chlorotoxin-redirected CAR T cells for patients with recurrent glioblastoma (SITC 2023)
    Results Here we report clinical outcomes and correlative observations for four lead-in research participants, all of whom had a histopathological diagnosis of glioblastoma, idh wild type, grade 4, and who had received prior temozolomide as well as radiation and other treatments. Conclusions Phase 1 clinical observations to date confirm the feasibility and safety of CLTX-CAR T cell immunotherapy for patients with GBM. These studies will lead to determination of a maximum tolerated dose/maximum feasible dose.
    Clinical • Late-breaking abstract • CAR T-Cell Therapy • IO biomarker
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    temozolomide • CHM 1101
    over1year
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1b, N=42, Recruiting, Chimeric Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jun 2023
    Enrollment open • Trial initiation date • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    almost2years
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    almost2years
    Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    MMP2-H
    |
    CHM 1101
    2years
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1b, N=42, Not yet recruiting, Chimeric Therapeutics
    New P1 trial • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type • MMP2-H
    |
    CHM 1101
    3years
    Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells? (SNO 2021)
    Diffuse distribution of CLTX.Cy5.5 was also seen in fixed xenograft sections of PBT003-4, PBT1206, PBT030-2, PBT051 and PBT138 tumor cells, and not obviously associated with more discrete staining for IL13Rα2 and EGFR. Ongoing experiments are further examining association of CLTX with other putative components of CLTX receptor complexes, and their redistribution during binding by CLTX and CLTX-CAR T cells.
    CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • NRP1 (Neuropilin 1)
    |
    CHM 1101
    3years
    Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma (SNO 2021)
    Ongoing studies are evaluating biomarkers of response and resistance, including CAR T cell activation and inflammatory cytokines. This clinical study provides first-in-human evidence for the safety and feasibility of CLTX-CAR T cells as a new class of toxin-based CARs for treatment of GBM.
    Clinical • CAR T-Cell Therapy
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    CHM 1101
    over3years
    [VIRTUAL] A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392). (ASCO 2021)
    CLTX-CAR T cells specifically and broadly target GBM through recognition of a receptor complex including membrane-bound matrix metalloprotease 2 (MMP-2)...Time to progression, overall survival, and disease response by Response Assessment in Neuro-Oncology (RANO) criteria, will be evaluated and descriptively compared to historical data . The study is actively enrolling patients.
    Clinical • P1 data
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MMP2 (Matrix metallopeptidase 2)
    |
    HER-2 expression • EGFR expression
    |
    CHM 1101